Angiopoietin-2 in the perinatal period and the role of intrauterine growth restriction

Acta Obstetricia et Gynecologica Scandinavica

Volumn 85, Issue 1, 2006, Pages 45-48

  Malamitsi Puchner, Ariadne ^a   Boutsikou, Theodora ^a   Economou, Emmanuel ^a   Tzonou, Anastasia ^a   Makrakis, Evangelos ^a   Nikolaou, Konstantinos ^a   Hassiakos, Dimitrios ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Angiopoietin 2; Intrauterine growth restriction; Neonate; Perinatal period; Umbilical cord

Indexed keywords

ANGIOPOIETIN 2;

ADULT; ANGIOGENESIS; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; FETUS; FETUS HYPOXIA; GESTATIONAL AGE; HUMAN; HYPERTENSION; IMMUNOASSAY; INTRAUTERINE GROWTH RETARDATION; MALE; NEWBORN; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; STATISTICAL ANALYSIS; STUDENT T TEST; UMBILICAL CORD BLOOD; BLOOD; FETUS BLOOD; PREGNANCY; PROSPECTIVE STUDY;

ADULT; ANGIOPOIETIN-2; FEMALE; FETAL BLOOD; FETAL GROWTH RETARDATION; HUMANS; INFANT, NEWBORN; MALE; PREGNANCY; PROSPECTIVE STUDIES;

EID: 33645641330     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340500334786     Document Type: Article

References (22)

1. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996;87:1160-9.
2. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55-60.
3. Valenzuela DM, Griffiths J, Rojas J, Aldrich TH, Jones PF, Zhou H, et al. Angiopoietin 3 and diverging gene counterparts in mouse and man. Proc Natl Acad Sci USA. 1999;96:1904-9.
4. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242-8.
5. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389-95.
6. Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD, Isner JM. Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J Biol Chem. 1998;273:18514-21.
7. Geva E, Ginzinger DG, Zaloudek CJ, Moore DH, Byrne A, Jaffe RB. Human placental vascular development: vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1 and angiopoietin-2. J Clin Endocrinol Metab. 2002;87:4213-24.
8. Jones PF. Not just angiogenesis - wider roles for the angiopoietins. J Pathol. 2003;201:515-27.
9. Mandriota SJ, Pepper MS. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res. 1998;83:852-9.
10. Oh H, Takagi H, Suzuma K, Otani A, Matsumura M, Honda Y. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem. 1999;274:15732-9.
11. Yuan HT, Yang SP, Woolf AS. Hypoxia up-regulates angiopoietin-2, a Tie-2 ligand, in mouse mesangial cells. Kidney Int. 2000;58:1912-9.
12. Mandriota SJ, Pyke C, Di Sanza C, Quinodoz P, Pittet B, Pepper MS. Hypoxia-inducible angiopoietin-2 expression is mimicked by iodonium compounds and occurs in the rat brain and skin in response to systemic hypoxia and tissue ischemia. Am J Pathol. 2000;156:2077-89.
13. Krikun G, Schatz F, Finlay T, Kadner S, Mesia A, Gerrets R, et al. Expression of angiopoietin-2 by human endometrial endothelial cells: regulation by hypoxia and inflammation. Biochem Biophys Res Commun. 2000;275:159-63.
14. Pollack RN, Divon MY. Intrauterine growth retardation: definition, classification and etiology. Clin Obstet Gynecol. 1992;35:99-107.
15. Regnault TRH, Galan HL, Parker TA, Anthony RV. Placental development in normal and compromised pregnancies - a review. Placenta. 2002;23(Suppl A):S119-29.
16. Khaliq A, Dunk C, Jiang J, Shams M, Li XF, Acevedo C, et al. Hypoxia down-regulates placenta growth factor, whereas fetal growth restriction up-regulates placenta growth factor expression: molecular evidence for "placental hyperoxia" in intrauterine growth restriction. Lab Invest. 1999;79:151-70.
17. Gardosi J, Chang A, Kaylan B, Sahota D, Symonds EM. Customised antenatal growth charts. Lancet. 1992;339:283-7.
18. Gardosi J, Mongelli M, Wilcox M, Chang A. An adjustable fetal weight standard. Ultrasound Obstet Gynecol. 1995;6:168-74.
19. Cooper JC, Sharkey AM, Charnock-Jones DS, Palmer CR, Smith SK. VEGF mRNA levels in placentae from pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol. 1996;103:1191-6.
20. Lyall F, Young A, Boswell F, Kingdom JC, Greer IA. Placental expression of vascular endothelial growth factor in placentae from pregnancies complicated by pre-eclampsia and intrauterine growth restriction does not support placental hypoxia at delivery. Placenta. 1997;18:269-76.
21. Dunk C, Shams M, Nijjar S, Rhaman M, Qui Y, Bussolati B, et al. Angiopoietin-1 and angiopoietin-2 activate trophoblast Tie-2 to promote growth and migration during placental development. Am J Pathol. 2000;156:2185-99.
22. Gale NW, Thurston G, Hackett SF, Renard R, Wang Q, McClain J, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell. 2002;3:411-23.